Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | IDH2 | P48735 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMO | Q99835 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30743834 | 1.00 | KDM4E (0.53) | KDM4ECYP2C19AOC3ALDH1A1LMNA | |
| SCHEMBL1874079 | 0.88 | KDM4E (0.61) | KDM4ECYP2C19ALDH1A1LMNAMAPT | |
| SCHEMBL29593693 | 0.83 | KDM4E (0.46) | KDM4ECYP2C19ALDH1A1LMNAMAPT | |
| SCHEMBL14689157 | 0.82 | SCD (0.45) | AOC3PDE10A | |
| SCHEMBL3510673 | 0.80 | CDK1 (0.46) | AOC3PDE10AIDH2SMO | |
| SCHEMBL24184396 | 0.79 | AOC3 (0.49) | KDM4EAOC3PDE10AIDH2 | |
| SCHEMBL2790748 | 0.79 | AOC3 (0.52) | AOC3PDE10AIDH2SMO | |
| SCHEMBL24184102 | 0.79 | AOC3 (0.49) | KDM4EAOC3PDE10AIDH2 | |
| SCHEMBL2791898 | 0.79 | AOC3 (0.52) | AOC3PDE10AIDH2SMO | |
| SCHEMBL2790751 | 0.79 | AOC3 (0.52) | AOC3PDE10AIDH2SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190831-A1 | TRANSTHYRETIN STABILIZING COMPOUNDS | PROTEGO BIOPHARMA, INC. | 2024-06-13 | — | — | US | disclosed |
| WO-2023009585-A2 | TRANSTHYRETIN STABILIZING COMPOUNDS | PROTEGO BIOPHARMA, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023009585-A2 | TRANSTHYRETIN STABILIZING COMPOUNDS | PROTEGO BIOPHARMA, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-7205417-B2 | Spiro compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| US-20050004092-A1 | Penem derivatives and antimicrobial agent containing the same | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-0757051-B1 | PENEM DERIVATIVES AND ANTIMICROBIAL AGENT CONTAINING THE SAME | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2003-10-29 | — | — | EP | disclosed |
| EP-0774465-A1 | Penem derivatives and antimicrobial agents containing the same | SUNTORY LIMITED (JP) | 1997-05-21 | — | — | EP | disclosed |
| EP-0757051-A1 | PENEM DERIVATIVES AND ANTIMICROBIAL AGENT CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1997-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004092-A1 | Penem derivatives and antimicrobial agent containing the same | MRPL21, MRPS2, MRPS28 | KDM4E 1902/4885CYP2C19 3170/4885AOC3 969/4885 |
| US-20240190831-A1 | TRANSTHYRETIN STABILIZING COMPOUNDS | TTR, TTPA, MTPN | KDM4E 4726/4885CYP2C19 4571/4885AOC3 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.